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Hormone replacement therapy after surgery for stage 1 or 2
cutaneous melanoma
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A total of 206 women were followed for a minimum of 5 years after primary melanoma surgery to establish if hormone replacement
therapy (HRT) adversely affected prognosis. In all, 123 had no HRT and 22 have died of melanoma; 83 had HRT for varying periods
and one has died of melanoma. After controlling for known prognostic factors, we conclude that HRT after melanoma does not
adversely affect prognosis.
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There is very little literature on the safety of hormone replacement
therapy (HRT) for women after diagnosis and apparently
successful treatment for melanoma. Two studies, one from
Denmark (Osterlind et al, 1988) and a recent large study from
Sweden (Persson et al, 1996), both suggest that HRT is not a risk
factor for melanoma development, but no study has been found in
the literature suggesting that HRT after melanoma diagnosis
affects the prognosis. Despite this, package inserts for HRT warn
women that caution should be exercised in taking HRT after
melanoma diagnosis. The relevant introductory paragraph on HRT
in the British National Formulary freely acknowledges that
‘evidence for caution in melanoma is unsatisfactory and many
women may stand to benefit from HRT’ (Joint formulary
committee, 2003).
It is therefore not surprising that in melanoma follow-up clinics,
a common request from general practitioners is advice on whether
or not HRT is contraindicated.
At present in the UK, approximately 3000 women annually will
be newly diagnosed with invasive melanoma and, as the average
age at diagnosis is in the early 50s (MacKie et al, 2002), a high
proportion of these women may wish to be considered for HRT
therapy.
We therefore undertook this study to provide an evidence base
for offering advice to women on the safety or hazard of HRT after
surgery for primary melanoma.
METHODS
The study has full ethical committee approval.
All women in the west of Scotland with melanoma diagnosed
between 1990 and 1995, who had been born between 1935 and
1950, were identified from the records of the west of Scotland
section of the Scottish Melanoma Group.
Decisions on HRT therapy were made purely by the general
practitioner looking after the patient or by the patient’s
gynaecologist, not by the individual in charge of melanoma
follow-up. All patients were followed up for a minimum of 5 years,
and the current median follow-up time is 10.6 years.
Melanoma was confirmed in every case and the significant
prognostic features of tumour thickness and ulceration were
reviewed. Follow-up recorded whether the patient was alive and
melanoma free, alive with recurrent melanoma, dead as a result of
melanoma or dead of other causes.
Statistical methods
Univariate analyses for categorical variables were performed using
a Chi-squared test of association. Continuous variables were
analysed using t-tests or Mann–Whitney tests where appropriate.
Kaplan–Meier and stepwise Cox regression analyses were used to
model the melanoma-free time data uni- and multivariately,
respectively.
RESULTS
A total of 225 women were eligible to enter the study. Information
on HRT status and complete melanoma follow-up data were
available for 206 (92%) women. In all, 123 women (60%) had
received no HRT at any time; 83 received HRT at some time for
periods ranging from 1 month to 19 years as shown in Figure 1.
The majority of women received HRT for less than 3 years, mainly
for perimenopausal symptoms. A total of 21 women with no uterus
had pure oestrogen replacement and 62 had a variety of combined
oestrogen/progesterone preparations. One of these women has
died of melanoma after having had combined oestrogen/proges-
terone HRT for 12 months, two are currently alive with recurrent
melanoma having had HRT for 7 and 10 years, respectively, and 80
remain alive and melanoma free. Revised 12 November 2003; accepted 27 November 2003
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lThe main prognostic factors for malignant melanoma
are tumour thickness and ulceration. Minor factors may be
histogenetic type, body site, deprivation category and age. The
distributions of these factors for the HRT-positive and
HRT-negative groups are shown in Table 1. Women in the
HRT-positive group were younger and had a lower proportion
of ulceration than those in the HRT-negative group. There
was no difference in the median tumour thickness in the
HRT-positive (0.90mm) and HRT-negative (1.00mm) groups
(P¼0.735).
Univariate analysis shows a highly significant survival difference
in favour of the HRT-treated group (P¼0.004). However, the
group not offered HRT have a higher proportion of ulcerated
primary tumours, recognised as a major prognostic factor (Balch
et al, 2001a). Once this is controlled for in a multivariate analysis,
the significance is reduced but still maintained (P¼0.007).
Tumour thickness was not significantly different between the
HRT-positive and -negative groups. The mean age of the HRT-
negative group was higher than the HRT-positive group, but when
this enters the model the significance of the survival difference is
unchanged (P¼0.007) (Table 2).
Table 3 shows the details of all patients dying of melanoma, and
illustrates the fact that the range of primary tumour thickness, and
time from diagnosis to death is wide.
The final model, based on a stepwise Cox regression, adjusting
for ulceration, tumour thickness and age, still showed a survival
difference in favour of the HRT-positive group (HR¼0.173; 95%
CI (0.048, 0.621)).
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Figure 1 Number of women taking HRT for specified number of years.
Table 2 Statistical analyses of HRT
+ and HRT
  cases
HRT
+ HRT
 
Number of cases 83 123
Alive and disease free 80 93
Alive with disease 2 4
Died of melanoma 1 22
Died of other causes 0 4
Cox regression HR (95% CI) HR P-value
Unadjusted 0.167 (0.050, 0.555) 1 0.004
Adjusted for ulceration 0.189 (0.057, 0.634) 1 0.007
Adjusted for ulceration and primary tumour thickness 0.136 (0.039, 0.480) 1 0.002
Adjusted for ulceration, primary tumour thickness and age 0.173 (0.048, 0.621) 1 0.007
HR¼hazard ratio.
Table 1 Baseline characteristics in HRT
+ and HRT
  cases
HRT
+ HRT
 
n (%) n (%) P-value
Ulceration
Yes 5 (6.2) 21 (17.8) 0.017*
Patients with tumours o1mm thick 42 (50.6) 58 (47.2) 0.627*
Patients with
Superficial spreading melanoma 60 (73.2) 84 (69.4) 0.846*
Nodular/polypoid melanoma 15 (18.3) 25 (20.7)
Lentigo maligna melanoma 4 (4.9) 4 (4.3)
Acral/mucosal melanoma 1 (1.2) 2 (1.7)
Other and unspecified melanoma 2 (2.4) 6 (5.0)
Patients with lesions on
Limbs 59 (72.0) 79 (65.3) 0.602*
Hands and feet 3 (3.7) 6 (5.0)
Other body parts 20 (24.4) 36 (29.8)
Deprivation category
1 and 2 26 (31.7) 32 (26.5) 0.034*
3, 4 and 5 50 (61.0) 64 (52.9)
6 and 7 6 (7.3) 25 (20.7)
Age
Mean 48.65 50.52 0.009**
*w
2 test of association. ** t-test.
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lDISCUSSION
The object of this study was to prove that HRT therapy was not
disadvantageous to women who had received apparently successful
surgery for AJCC stage 1 or 2 melanoma. The ideal study to prove
this would have been a randomised controlled study, with all
women who had had melanoma treated and then wished HRT
randomised to receive HRT or placebo. This was not practical in
terms of numbers of patients available and willing to give informed
consent to be entered into such a study. We therefore carried out
this prospective observational study.
Reports from the UK (Ballard, 2002) indicate that 60% of women
aged 51–57 years have had some form of HRT, and from the US
that 40% of women have had HRT by their 50th birthday (Fletcher
and Colditz, 2002). The UK data compared with the 40% of
melanoma patients receiving HRT in our study indicate that
currently fewer melanoma patients are prescribed HRT than in the
general population. It appears that general practitioners and
gynaecologists caring for these patients currently select patients in
the better prognosis group for HRT as shown by the imbalance in
ulcerated melanomas between those who did and did not receive
HRT. It is also apparent that the majority of melanoma patients for
whom HRT is prescribed receive it for less than 3 years, mainly for
perimenopausal symptoms, rather than for long-term prevention
of osteoporosis.
Our results show that HRT as used in this cohort of women
appears to have no adverse effect on outcome after surgery for
localised melanoma and indeed suggests that such therapy may
improve prognosis. It is obviously vital to ensure that an
imbalance of recognised prognostic factors between the two
groups does not explain this unexpected observation. The major
currently recognised prognostic factors include tumour thickness
and ulceration. As is reported, we found over-representation of
women with ulcerated melanomas in the group not receiving HRT,
but melanoma thickness was not significantly different between
the groups. We have previously reported that women in higher
socioeconomic groups have better survival prospects than those in
the less-affluent groups (MacKie and Hole, 1996), but again
controlling for this did not remove the apparent survival
advantage in receiving HRT. Younger women with melanoma
have a survival advantage over postmenopausal women
(Balch et al, 2001b), so it may be that by restoring the endocrine
milieu in these women to a premenopausal state, the survival
advantage is real.
This study was completed before the results of the WHI
(Chlebowski et al, 2003), and million women (Million Women
Study Collaborators, 2003) studies reported an increased incidence
in breast cancers in women receiving HRT of all types, and also an
increase in breast cancer mortality in women on HRT in the
million women study. These disturbing data will clearly radically
alter the current approach to the use of both short- and long-term
use of HRT in all women. However, the data on HRT and
melanoma obtained in this study indicate that women who have
had stage 1 or 2 melanoma successfully treated should be
considered for HRT in the same way as those who have never
had melanoma.
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Table 3 Details of patients who have died of melanoma
Age at melanoma
diagnosis
Primary tumour
thickness (mm)
Time from melanoma
diagnosis to death
HRT+ 55 2.0 6 months
HRT  46 1.6 2 years
HRT  46 3.1 3 years
HRT 54 1.9 3 years
HRT 57 3.9 1 year
HRT  55 1.7 1 year
HRT  44 3.8 6 months
HRT  46 5.0 2 years
HRT  55 1.8 2 years
HRT  55 1.1 10 years
HRT  56 5.7 2 years
HRT  55 0.6 6 years
HRT  55 9.0 1 year
HRT  59 0.5 3 years
HRT  46 1.5 4 years
HRT  59 5.7 1 year
HRT  49 0.5 7 years
HRT  48 4.3 10 years
HRT  56 3.0 1 year
HRT  51 1.1 7 years
HRT  45 1.7 4 years
HRT  50 4.0 1 year
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